| Literature DB >> 34952873 |
Xiaoyi Shu1, Ciara McConaghy2, Alec Knight3.
Abstract
PURPOSE: To evaluate published evidence on the Modified Tardieu Scale (MTS) as a tool to assess spasticity in the upper limbs of adults with neurological conditions. DATA SOURCES: A systematic search of six electronic databases (PubMed/MEDLINE, CINAHL, EMBASE, the Cochrane Library, Web of Science and Physiotherapy Evidence Database) from inception to 31 December 2020. A search strategy was developed using key elements of the research question: population, intervention (action), outcome. STUDY ELIGIBILITY CRITERIA: Inclusion criteria: (1) adult participants with neurological conditions; (2) upper limb muscles/joints as tested elements; (3) studies testing the MTS and (4) reliability or validity reported. EXCLUSION CRITERIA: (1) non-English articles; (2) non-empirical articles and (3) studies testing the Tardieu Scale. STUDY APPRAISAL: Evidence quality was evaluated using the US National Heart, Lung, Blood Institute quality assessment tool for observational cohort and cross-sectional studies.Entities:
Keywords: multiple sclerosis; rehabilitation medicine; stroke
Mesh:
Year: 2021 PMID: 34952873 PMCID: PMC8712979 DOI: 10.1136/bmjopen-2021-050711
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart of the study identification and inclusion process.
Data extraction table for MTS studies reporting reliability and validity data
| Reliability studies | ||||||
| Author | Study design | Participants | Test characteristics | Summary of results | ||
| Inter-rater reliability | Intrarater reliability | Test–retest reliability | ||||
| Sonvane and Kumar | Cross-sectional study |
n=60 Stroke Source of participants not specified |
Tested muscle: elbow flexors Testing position: sat on a chair with shoulder in adduction for elbow flexors Testing time and interval: unspecified time with a 2-day interval Testing speed: counting 1001, 1002, 1003… (V1), count 1, 2, 3… (V3) Measurement instrument: goniometer on specific body landmark Rater training: not specified MTS version: not specified | – | – | R1: r=0.973, p<0.001 |
| Singh | Cross-sectional study |
n=91 Stroke Hospital admissions |
Tested muscle: elbow flexors Testing position: sat on a chair with shoulder in adduction for elbow flexors Testing time and interval: a 2-day intervals Testing speed: counting 1001, 1002, 1003… (V1) count 1, 2, 3… (V3) Measurement instrument: goniometer with specific body landmarks Rater training: trained by two experienced neurophysiotherapists, but no further details MTS version: 5-point scale | – | R1: ICC: 0.998; CI: 0.997 to 0.999 | – |
| Li | Cross-sectional study |
n=51 Stroke Consecutive admissions to a hospital ward |
Tested muscle: elbow flexors Testing position: supine with arm by the side and head in neutral position Testing time and interval: 7:00 and 8:30 with a 1-day interval Testing speed: as slow as possible (V1), as fast as possible (V3) Measurement instrument: not specified Rater training: not specified MTS version: 6-point scale | R1:ICC:0.78; CI: 0.64 to 0.87 | R1: ICC: 0.71; CI: 0.53 to 0.82 | – |
| Waninge | Cross-sectional study |
n=35 Profound intellectual and multiple disabilities Source of participants not specified |
Tested muscle: elbow (muscle group not specified) Testing position: unknown protocol specified in a Dutch language article Testing time and interval: time not specified with a 1-week interval Testing speed: slow motion within 1 s (V1), fast motion within half second (V3) Measurement instrument: goniometer Rater training: trained in using protocol but not the scale MTS version: not specified | R1: p level: 0.886; ICC: 0.806; LOA: 40; SCC: 0.813 | – | R1: p level: 0.592; ICC: 0.815; LOA: 35.2; SCC: 0.792 |
| Ansari | Cross-sectional study |
n=30 Brain injury leading to hemiplegia Participants attended a rehabilitation clinic |
Tested muscle: elbow flexors Testing position: sat on a chair with shoulder in adduction Testing time and interval: not specified Testing speed: not specified Measurement instrument: goniometer Rater training: no formal training MTS version: 5-point scale Others: raters were blinded to the results | R1: ICC: 0.74; CI: 0.52 to 0.87 | – | – |
| Mehrholz | Cross-sectional study |
n=30 Severe brain injury patients Attending rehabilitation department |
Tested muscle: Shoulder flexor and external rotator, elbow flexor and extensors, wrist flexors and extensors Testing position: supine with the arm by the body, elbow in extension, wrist in a neutral position. Then the elbow was extended from maximal flexion position Testing time and interval: 9:00–10:00 with a 10 minutes interval Testing speed: as slow as possible (V1), as fast as possible (V3) Measurement instrument: goniometer Rater training: 45 minutes training session MTS version: 6-point scale Others: raters were blinded to the results | R1 ( | – | R1 ( |
CI, 95% Confidence Interval; Hmax/Mmax, maximum mean amplitude of the H-reflex relative to maximum mean amplitude of the M-wave; Hslp, the developmental slope of the H-reflex; Hslp/Mslp, the developmental slope of the H-reflex recruitment curve relative to the developmental slope of the M-response; ICC, intraclass correlation coefficient; LOA, limits of agreement; MAS, Modified Ashworth Scale; MTS, Modified Tardieu Scale; r, Pearson’s correlation coefficient; SCC, Spearman correlation coefficient.
Quality assessment tool for observational cohort and cross-sectional studies
| Criteria | Study authors | ||||||
| Sonvane and Kumar | Singh | Li | Waninge | Ansari | Mehrholz | Naghdi | |
| 1. Was the research question or objective in this paper clearly stated? | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 2. Was the study population clearly specified and defined? | No | Yes | No | No | No | Yes | No |
| 3. Was the participation rate of eligible persons at least 50% | NR | Yes | NR | Yes | NR | Yes | NR |
| 4. Were all the subjects selected or recruited from the same or similar populations (including the same time)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | CD | Yes | Yes | Yes | CD | Yes | CD |
| 5. Was a sample size justification, power description, or variance and effect estimates provided? | No | No | No | No | No | No | No |
| 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | NA | NA | NA | NA | NA | NA | NA |
| 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | NA | NA | NA | NA | NA | NA | NA |
| 8. For exposures that can vary in amount of level, did the study examine different levels of the exposure and outcome? | NA | NA | NA | NA | NA | NA | NA |
| 9. Were the exposure measures (independent variables) clearly defined, valid, reliable and implemented across all study participants? | Yes | Yes | Yes | No | Yes | Yes | Yes |
| 10. Was the exposure(s) assessed more than once over time? | NA | NA | NA | NA | NA | NA | NA |
| 11. Were the outcome measure (dependent variables) clearly defined, valid, reliable and implemented across all study participants? | No | No | Yes | No | No | Yes | Yes |
| 12. Were the outcome assessors blinded to the exposure status of participants? | NR | Yes | NR | NR | Yes | Yes | NR |
| 13. Was loss to follow-up after baseline 20% or less? | NA | NA | NA | NA | NA | NA | NA |
| 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | No | No | No | Yes | No | Yes | No |
| Quality rating | Poor | Fair | Poor | Poor | Poor | Good | Poor |
Quality rating categories adapted from Sommer et al20 : ‘poor: ≤50%; fair: 50%–75%; good≥75%’.
CD, cannot determine; NR, not reported.